Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Non-Current Debt (2019 - 2024)

Historic Non-Current Debt for Spero Therapeutics (SPRO) over the last 6 years, with Q3 2024 value amounting to $13000.0.

  • Spero Therapeutics' Non-Current Debt fell 7903.23% to $13000.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $13000.0, marking a year-over-year decrease of 7903.23%. This contributed to the annual value of $87000.0 for FY2023, which is 937.5% down from last year.
  • Spero Therapeutics' Non-Current Debt amounted to $13000.0 in Q3 2024, which was down 7903.23% from $25000.0 recorded in Q2 2024.
  • In the past 5 years, Spero Therapeutics' Non-Current Debt ranged from a high of $205000.0 in Q1 2020 and a low of $13000.0 during Q3 2024
  • Its 5-year average for Non-Current Debt is $116105.3, with a median of $117000.0 in 2022.
  • In the last 5 years, Spero Therapeutics' Non-Current Debt tumbled by 937.5% in 2023 and then crashed by 7903.23% in 2024.
  • Spero Therapeutics' Non-Current Debt (Quarter) stood at $177000.0 in 2020, then fell by 22.03% to $138000.0 in 2021, then crashed by 30.43% to $96000.0 in 2022, then dropped by 9.38% to $87000.0 in 2023, then tumbled by 85.06% to $13000.0 in 2024.
  • Its Non-Current Debt was $13000.0 in Q3 2024, compared to $25000.0 in Q2 2024 and $38000.0 in Q1 2024.